newsfilter
← Latest News
ACCESS Newswire·

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

  • Protagenic Therapeutics (NASDAQ: PTIX) received a notification from Nasdaq stating it is non-compliant with Listing Rules 5550(b)(1) & 5250(c)(1).
  • The company fails to meet the $2.5 million minimum stockholders' equity requirement based on its June 30, 2025 Form 10-QT report.
  • Non-compliance also stems from the delayed filing of the Form 10-Q for the quarter ended September 30, 2025.
  • Nasdaq has determined to delist the company's securities under Rule 5815 despite a recent restoration of compliance & ongoing monitoring.
  • The company plans to timely request a hearing before the Nasdaq Hearings Panel & present its plan to address both deficiencies.
  • Filing the hearing request automatically stays any suspension for 15 calendar days & the company will also request an extended stay pending the decision.
  • The company expects to file the missing Form 10-Q imminently & its stock will continue trading during any granted stay period.
  • No assurance exists that the Panel will grant an extended stay or that the company will meet all Nasdaq compliance standards.